Clinical Trials Logo

Co-morbidity clinical trials

View clinical trials related to Co-morbidity.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05911321 Recruiting - Multiple Myeloma Clinical Trials

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that has returned or has not responded to prior treatment. The study will specifically investigate the impact of administering lower-than-standard doses of pomalidomide and dexamethasone. Using lower doses of pomalidomide and dexamethasone in this setting has not been approved by the Food and Drug Administration (FDA).